Related Experiment Video
Updated: Aug 23, 2026

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
Published on: December 3, 2019
Update in HIV-associated lymphoma
1Division of Hematology, Memorial Sloan-Kettering Cancer, Weill Medical College of Cornell University, New York, New York 10021, USA. noya@mskcc.org
Purpose Of Review:
Infection with human immunodeficiency virus (HIV) is associated with an increased risk of non-Hodgkin lymphoma and Hodgkin disease. This review summarizes developments within the past 18 months.
Recent Findings:
Investigators continue to demonstrate that many standard therapies similar to those used in the non-HIV- infected population may be used in the HAART era for patients infected with HIV. Biologic differences do exist, however, and not all treatments and outcomes are directly translatable. Some treatments, such as rituximab in combination with CHOP, may have unforeseen toxicity. Nonetheless, high-dose therapy does appear feasible and may offer curative therapy for those with refractory and relapsed disease.
Summary:
HIV-infected persons appear to benefit from most, but not all standard treatments for lymphoma.
Related Concept Videos
Retrovirus Life Cycles
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Treatment Resistent Cancers
Cryptococcal Meningitis